Table 2.
Baseline characteristics of tocilizumab-treated patients (N = 5462)a, classified according to RA duration
| Baseline characteristics | RA duration |
|||||
|---|---|---|---|---|---|---|
| <6 months, n = 44 | 6 months– 2 years, n = 1279 | >2–5 years, n = 1274 | >5–10 years, n = 1173 | >10 years, n = 1692 | All patients, n = 5462 | |
| Female, n (%) | 35 (79.5) | 982 (76.8) | 1027 (80.6) | 962 (82.0) | 1414 (83.6) | 4420 (80.9) |
| White, n (%) | 36 (81.8) | 1037 (81.1) | 1012 (79.4) | 901 (76.8) | 1381 (81.6) | 4367 (80.0) |
| Age, mean (s.d.), years | 51.1 (15.1) | 51.7 (13.2) | 51.5 (12.9) | 52.3 (12.4) | 56.7 (10.3) | 53.3 (12.3) |
| Region, n (%) | ||||||
| Europe | 21 (47.7) | 450 (35.2) | 508 (39.9) | 507 (43.2) | 670 (39.6) | 2156 (39.5) |
| North America | 21 (47.7) | 590 (46.1) | 451 (35.4) | 335 (28.6) | 558 (33.0) | 1955 (35.8) |
| South America | 2 (4.5) | 139 (10.9) | 196 (15.4) | 204 (17.4) | 229 (17.7) | 840 (15.4) |
| Rest of world | 0 | 100 (7.8) | 119 (9.3) | 127 (10.8) | 165 (9.8) | 511 (9.4) |
| BMI, mean (s.d.), kg/m2 | 28.7 (7.7) | 29.1 (7.1) | 28.3 (6.6) | 27.9 (6.4) | 27.4 (5.7) | 28.1 (6.4) |
| No. of previous csDMARDs, mean (s.d.) | 1.2 (0.5) | 1.4 (0.7) | 1.6 (0.8) | 1.7 (0.9) | 1.9 (1.1) | 1.7 (0.9) |
| Use of oral glucocorticoids, n (%) | 24 (54.5) | 656 (51.3) | 639 (50.2) | 628 (53.5) | 892 (52.7) | 2839 (52.0) |
| Oral glucocorticoid dose, mean (s.d.), mg/dayb | 7.3 (2.5) | 7.0 (3.1) | 6.7 (3.0) | 6.9 (4.6) | 6.7 (5.3) | 6.8 (4.2) |
| RF positive, n (%) | 19 (59.4) | 554 (64.4) | 638 (75.3) | 633 (80.5) | 955 (81.6) | 2779 (75.8) |
| CRP, mean (s.d.), mg/dl | 2.3 (2.6) | 2.0 (2.6) | 1.9 (2.5) | 2.1 (2.7) | 1.9 (2.3) | 2.0 (2.5) |
| HAQ-DI, mean (s.d.) | 1.4 (0.7) | 1.5 (0.6) | 1.5 (0.6) | 1.5 (0.6) | 1.6 (0.6) | 1.5 (0.6) |
| DAS28, mean (s.d.) | 6.3 (1.1) | 6.4 (1.1) | 6.4 (1.1) | 6.5 (1.0) | 6.4 (1.1) | 6.4 (1.1) |
| CDAI, mean (s.d.) | 37.5 (13.4) | 39.8 (13.7) | 39.0 (13.9) | 39.0 (13.3) | 39.4 (13.6) | 39.3 (13.6) |
a
RF positivity was not assessed in three studies (ROSE, ACT-STAR and ACT-SURE) and was only available in a minority of patients in ACT-RAY; HAQ-DI data were not assessed in two studies (ROSE and ACT-STAR); BMI was not assessed in one study (ACT-SURE). bIn prednisone equivalents. CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic DMARD; DAS28: DAS based on 28 joints; HAQ-DI: HAQ–Disability Index.